PT  - JOURNAL ARTICLE
AU  - Gupta, Mohak
AU  - Mohanta, Saptarshi Soham
AU  - Rao, Aditi
AU  - Parameswaran, Giridara Gopal
AU  - Agarwal, Mudit
AU  - Arora, Mehak
AU  - Mazumder, Archisman
AU  - Lohiya, Ayush
AU  - Behera, Priyamadhaba
AU  - Bansal, Agam
AU  - Kumar, Rohit
AU  - Meena, Ved Prakash
AU  - Tiwari, Pawan
AU  - Mohan, Anant
AU  - Bhatnagar, Sushma
TI  - Transmission dynamics of the COVID-19 epidemic in India and modelling optimal lockdown exit strategies
AID  - 10.1101/2020.05.13.20096826
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.13.20096826
4099  - http://medrxiv.org/content/early/2020/05/22/2020.05.13.20096826.short
4100  - http://medrxiv.org/content/early/2020/05/22/2020.05.13.20096826.full
AB  - Background The SARS-CoV-2 pandemic has quickly become an unprecedented global health threat. India with its unique challenges in fighting this pandemic, imposed one of the world’s strictest and largest population-wide lockdown on 25 March 2020. Here, we estimated key epidemiological parameters and evaluated the effect of control measures on the COVID-19 epidemic in India. Through a modelling approach, we explored various strategies to exit the lockdown.Methods We obtained data from 140 confirmed COVID-19 patients at a tertiary care hospital in India to estimate the delay from symptom onset to confirmation and the proportion of cases without symptoms. We estimated the basic reproduction number (R0) and time-varying effective reproduction number (Rt) after adjusting for imported cases and reporting lag, using incidence data from 4 March to 25 April 2020 for India. We built upon the SEIR model to account for underreporting, reporting delays, and varying asymptomatic proportion and infectivity. Using this model, we simulated lockdown relaxation under various scenarios to evaluate its effect on the second wave, and also modelled increased detection through testing. We hypothesised that increased testing after lockdown relaxation will decrease the epidemic growth enough to allow for greater resumption of normal social mixing thus minimising the social and economic fallout.Results The median delay from symptom onset to confirmation (reporting lag) was estimated to be 2·68 days (95%CI 2·00–3·00) with an IQR of 2·03 days (95%CI 1·00–3·00). 60·7% of confirmed COVID-19 cases (n=140) were found to be asymptomatic. The R0 for India was estimated to be 2·083 (95%CI 2·044–2·122; R2 = 0·972), while the Rt gradually down trended from 1·665 (95%CI 1·539–1·789) on 30 March to 1·159 (95%CI 1·128–1·189) on 22 April. In the modelling, we observed that the time lag from date of lockdown relaxation to start of second wave increases as lockdown is extended farther after the first wave peak. This benefit was greater for a gradual relaxation as compared to a sudden lifting of lockdown. We found that increased detection through testing decreases the number of total infections and symptomatic cases, and the benefit of detecting each extra case was higher when prevailing transmission rates were higher (as when restrictions are relaxed). Lower levels of social restrictions when coupled with increased testing, could achieve similar outcomes as an aggressive social distancing regime where testing was not increased.Conclusions The aggressive control measures in India since 25 March have produced measurable reductions in transmission, although suppression needs to be maintained to achieve sub-threshold Rt. Additional benefits for mitigating the second wave can be achieved if lockdown can be feasibly extended farther after the peak of active cases has passed. Aggressive measures like lockdowns may inherently be enough to suppress the epidemic, however other measures need to be scaled up as lockdowns are relaxed. Expanded testing is expected to play a pivotal role in the lockdown exit strategy and will determine the degree of return to ‘normalcy’ that will be possible. Increased testing coverage will also ensure rapid feedback from surveillance systems regarding any resurgence in cases, so that geo-temporally targeted measures can be instituted at the earliest. Considering that asymptomatics play an undeniable role in transmission of COVID-19, it may be prudent to reduce the dependence on presence of symptoms for implementing control strategies, behavioral changes and testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Ethics Committee AIIMS Delhi; Ref. No. IECPG-166/23.04.2020All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code for the simulations and detailed results are available at the following GitHub repository: https://github.com/technosap/SEIR_QDPA-COVID_19. The primary data for calculation of reporting lag is available in the appendix. All other data is from publicly available datasets. https://github.com/technosap/SEIR_QDPA-COVID_19